Minafra M, Laforgia R, Sederino M G, Fedele S, Delvecchio A, Lattarulo S, Carbotta G, Fabiano G
G Chir. 2017 Sep-Oct;38(5):213-218. doi: 10.11138/gchir/2017.38.5.213.
The aim of our study is to focus on hTERT (human Telomerase Reverse Transcriptase) expression to identify tumoral tissue after a comparison to TP53 and KRAS. More than 85% of cancer cells contain genetic aberrations and also overexpression of hTERT, and, in fact, the promoter of hTERT characterizes all malignant cells.
Our sample is composed of 18 patients, including 10 with CRC that underwent surgical procedure and 8 patients without CRC, which represent the control group. The hTERT gene expression, KRAS and p53 were evaluated by methodical Real Time - PCR on RNA extracted from tumor tissues, peritumoral tissue and control cases.
Within the CRC group the evaluation of the tumor tissue showed an increase of hTERT expression with a statistical significance (> 0.1) in 5 of these, also associated with substantial increase of KRAS (> 0.2). The peritumoral tissue assessment showed important increase in KRAS in 4 patients (> 0.2), while hTERT is not found to be particularly increased. The value of p53 did not show any particular significance (<0.1).
The analysis of our data leads us to consider that the increase of hTERT is evident in patients suffering from CRC and that some of them will become significant in relation to the increase of KRAS and independent of p53. In peritumoral tissues, however, KRAS increases considerably, instead hTERT maintains a low concentration and this is compatible with the cellular evolution of the neoplastic tissue adjacent to the tumor.
hTERT could be used for diagnosis and prognosis in the future, to be able to identify the risk of tumor progression and to set up an adequate therapy.
我们研究的目的是聚焦于人类端粒酶逆转录酶(hTERT)的表达,通过与TP53和KRAS进行比较来识别肿瘤组织。超过85%的癌细胞存在基因畸变且hTERT过表达,事实上,hTERT的启动子是所有恶性细胞的特征。
我们的样本由18名患者组成,其中10名患有接受了外科手术的结直肠癌(CRC),8名无CRC的患者作为对照组。通过对从肿瘤组织、瘤周组织和对照病例中提取的RNA进行系统的实时聚合酶链反应(Real Time - PCR)来评估hTERT基因表达、KRAS和p53。
在CRC组中,对肿瘤组织的评估显示,其中5例hTERT表达增加且具有统计学意义(>0.1),同时KRAS也显著增加(>0.2)。瘤周组织评估显示,4例患者的KRAS显著增加(>0.2),而未发现hTERT有特别增加。p53的值未显示任何特别的意义(<0.1)。
对我们数据的分析使我们认为,hTERT的增加在患有CRC的患者中很明显,并且其中一些与KRAS的增加相关且独立于p53。然而,在瘤周组织中,KRAS显著增加,而hTERT维持低浓度,这与肿瘤相邻的肿瘤组织的细胞演变是相符的。
hTERT未来可用于诊断和预后,以便能够识别肿瘤进展的风险并制定适当的治疗方案。